Hu J, Lai C, Xiao Y, Yan Z, et al. Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer. Oncogene 2026 Aug 3. doi: 10.1038/s41388-026-03946.
PMID: 42547555